Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Brady Nelson

Physician Assistant, Medical Peoria, AZ Physician Assistant

NPI 1922103407 CMS profile 10858672

13943 N . 91St Ave Building I, Peoria, AZ 85381

Open in the dashboard

General payments

$10,834

562 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brady Nelson of Peoria, AZ is reported in the CMS Open Payments database as having received $10,834 across 562 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,228 158
2024 General $2,853 159
2023 General $3,002 145
2022 General $1,752 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brady Nelson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Brady Nelson were reported at $3,228. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Brady Nelson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $1,752 $185 $55–$649 $149
2023 $3,002 $199 $58–$717 $160
2024 $2,853 $206 $62–$740 $164
2025 $3,228 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Amgen Inc. $2,780 165 payments
  2. AbbVie, Inc. $2,135 103 payments
  3. UCB, Inc. $1,469 44 payments
  4. Janssen Biotech, Inc. $983 55 payments
  5. Pfizer Inc. $458 30 payments
  6. GlaxoSmithKline, LLC. $449 25 payments
  7. Novartis Pharmaceuticals Corporation $445 25 payments
  8. Radius Health, Inc. $305 14 payments
  9. Lilly USA, LLC $207 12 payments
  10. Horizon Therapeutics plc $187 16 payments
  11. Other $1,416 73 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $10,626 557 payments
  2. Education $209 5 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $1,618 77 payments
  2. Otezla $1,040 66 payments
  3. TREMFYA $983 55 payments
  4. Cimzia $930 26 payments
  5. Enbrel $793 49 payments
  6. EVENITY $687 36 payments
  7. Bimzelx $539 18 payments
  8. KRYSTEXXA $499 27 payments
  9. XELJANZ $458 30 payments
  10. BENLYSTA $449 25 payments
  11. Other $4,708 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

5,580

Median for Physician Assistant: 241

Drug cost

$3,649,056

Median for Physician Assistant: $4,110

Branded share of claims

19.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira Pen Adalimumab Brand 36 $379,139
Enbrel Etanercept Brand 34 $356,574
Otezla Apremilast Brand 70 $350,558
Humira(Cf) Pen Adalimumab Brand 46 $345,591
Actemra Tocilizumab Brand 111 $323,530
Cosentyx Sensoready (2 Pens) Secukinumab Brand 35 $281,655
Enbrel Sureclick Etanercept Brand 35 $260,555
Truxima Rituximab-Abbs Brand 12 $199,583
Cyltezo(Cf) Pen Adalimumab-Adbm Brand 22 $148,148
Xeljanz Xr Tofacitinib Citrate Brand 21 $134,580

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$516,600

Of which drugs: $435,949

Medicare patients

301

Average age 72

Services billed

40,901

235 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 45%
Diabetes 33%
Depression 33%
Chronic kidney disease 32%
Ischemic heart disease 28%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 44 4,260 $87,307
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 12 2,560 $63,518
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 60 622 $420
Injection, ketorolac tromethamine, per 15 mg J1885 Office 38 672 $315
Injection, zoledronic acid, 1 mg J3489 Office 13 65 $255
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 59 199 $169
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 21 121 $79

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$403 18 —
Cimzia
$276 — —
TREMFYA
$208 — —
Enbrel
$175 81 —
COSENTYX
$165 35 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

562 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record